Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...

A GROUP of parents whose children's deaths were linked to Dengvaxia vaccine said that the Department of Justice (DOJ) has ...

The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...

Sanofi's SNY +1.27% + Free Alerts short percent of float has risen 11.76% since its last report. The company recently ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Sanofi (NASDAQ:SNY) said that a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment of multiple myeloma met its co-primary endpoints, demonstrating non-inferiority to ...

Also Read: Sanofi’s 340B Credit Proposal Draws Federal Warning For Statutory Violation Key secondary endpoints were also achieved, including very good partial response, the incidence rate of ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in ...